Merck bets big on circular RNA, paying $150M and dangling $3.5B in biobucks to work with Orna NexImmune sizes up the competition and decides to pause myeloma T-cell therapy plans Homology, after raising gene therapy from clinical hold, pauses trial enrollment to save cash A year after FDA slammed on the breaks, BrainStorm is hitting the gas with updated data, approval plans Scientists home in on hormone linked with liver cancer in NASH cases CRISPR offers genetic clues to Alzheimer's in brain's cleaning crew After Trodelvy's approval in China, Gilead strikes $455M deal with Everest for Asian rights Health tech layoffs continue as Signify Health will cut nearly 500 jobs and Truepill reduces headcount, again AbbVie unveils new Skyrizi TV ads with a subtler tone compared to its revved-up Rinvoq approach AstraZeneca heads to court to contest former exec's move to crosstown rival GSK: report Philips CEO van Houten hands reins to head of beleaguered connected care business FTC warns states against laws permitting hospital mergers under special conditions Featured Story | By Nick Paul Taylor Orna Therapeutics is in the money. Tuesday morning, the developer of fully engineered circular RNA therapies revealed a double dose of good news, simultaneously taking the lid off an alliance with Merck & Co. worth $150 million upfront and a $221 million series B financing. read more |
| |
|---|
|
Top Stories By James Waldron NexImmune has cited tough competition as the reason for pausing enrollment on one of its two clinical candidates, as the company diverts resources into launching a solid tumor therapy into human studies. read more By Nick Paul Taylor Homology Medicines is now able to enroll patients in its HMI-102 gene therapy trial—but is choosing not to. Having persuaded the FDA to lift the clinical hold in June, the biotech has now paused enrollment in the phenylketonuria study to free up cash for a gene editing trial in the same population. read more By Max Bayer Almost a year and a half after the FDA spiked phase 3 data of BrainStorm's ALS therapy, the company is asking regulators for approval, pointing to amended figures. The company says that a new analysis of a subset of patients showed statistical significance. read more By Max Bayer Scientists from the University of Michigan have further uncovered the impact of a hormone secreted by fat cells in mice with NASH. When the hormone was knocked out in mice, there was an increase in tumor growth compared to the control. read more By Angus Liu A research team led by the University of California, San Francisco has identified genetic regulators of microglia’s disease states in the brain. The hope is to identify drugs that act on relevant genes or proteins to revert diseased microglia back to a healthy state to treat neurodegenerative diseases. read more By Angus Liu When Gilead Sciences acquired Immunomedics in 2020, another company owned certain rights to the deal's crown jewel Trodelvy. Now, Gilead thinks it’s time to take it back. read more By Heather Landi Digital health company Truepill has conducted its third round of layoffs in 2022, according to media reports. And Signify Health, the value-based home health provider reportedly being pursued by CVS Health, also cut its workforce as its shifts away from its episodes of care business. read more By Ben Adams This year, AbbVie has continually been a big spender in the TV ad drug stakes, and it’s showing no signs of slowing down. After launching two new Rinvoq commercials this summer, the Big Pharma is now turning its attention to its second immunology blockbuster, Skyrizi. read more By Fraiser Kansteiner Angling to keep trade secrets out of a local rival’s hands, AstraZeneca has asked a London court to enforce and extend a noncompete agreement, Bloomberg reports. read more By Andrea Park After weathering the storm of Philips' ongoing respiratory device recall for about a year, CEO Frans van Houten is stepping back from the helm. Taking his place as chief executive will be Roy Jakobs, who’s been heading up Philips’ response to the recall for months. read more By Dave Muoio "Despite hospital claims that [Certificates of Public Advantage laws] will result in lower costs and improved population health outcomes, we are not aware of any proven benefits," FTC Director of Policy Planning Elizabeth Wilkins said Monday. read more | | New Product Planning Summit September 19-20, 2022 | Boston, MA Join us for the ONLY conference for defining how the new product planning role and related functions make informed, value-based, data-driven decisions about products in the pipeline. Register now! |
|---|
Resources Sponsored by: Bio-Techne Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella. Sponsored by: Thermo Fisher Scientific Set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Speid & Associates, Inc. The total immersion, transformative training will take place at the Harvard Club in Boston. VIRTUAL in real time is also available. Contingencies for COVID19 will apply. Register NOW for a large early bird discount www.drugstomarket.com/drugbootcamp. Sponsored by: Triangle Insights Group, LLC The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services. Sponsored by: Thermo Fisher Scientific See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. | 